FDA
-
-
-
-
-
-
-
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
-
-
-
-
-
-
-
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
-
-
-
-
-
-
-
FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old
-
-
-
-
-
-
-
Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia
-
-
-
-
-
-
-
Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine
-
251,863 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All